CUSIP: 60463E103
Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
11,285,133
-
Share change
-
+2,378,891
-
Total reported value
-
$5,043,069
-
Price per share
-
$0.45
-
Number of holders
-
24
-
Value change
-
+$1,047,742
-
Number of buys
-
13
-
Number of sells
-
7
Quarterly Holders Quick Answers
What is CUSIP 60463E103?
CUSIP 60463E103 identifies MGEN - MIRAGEN THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2020
-
Previous quarter:
Q4 2019
Recent filing periods for CUSIP 60463E103:
Institutional Holders of MIRAGEN THERAPEUTICS INC - COM (MGEN) as of Q1 2020
As of 31 Mar 2020,
MIRAGEN THERAPEUTICS INC - COM (MGEN) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,285,133 shares.
The largest 10 holders included
FMR LLC, Atlas Venture Advisors, Inc., VANGUARD GROUP INC, Alyeska Investment Group, L.P., RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., JPMORGAN CHASE & CO, GEODE CAPITAL MANAGEMENT, LLC, Squarepoint Ops LLC, and NORTHERN TRUST CORP.
This page lists
24
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.